

Patient Name	: Ms Dummy	Bill Date	: Feb 16, 2024, 08:41 PM
DOB/Age/Gender	: 43 Y/Female	Sample Collected	: Feb 18, 2024, 07:43 AM
Patient ID / UHID	: XXX	Sample Received	: Feb 18, 2024, 12:07 PM
Referred By	: Dr.	Report Date	: Feb 18, 2024, 02:02 PM
Sample Type	: Serum	Report Status	: Final Report
Barcode No	: XXX		

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

## BIOCHEMISTRY REPORT

Lipoprotein (A)

Lipoprotein A	13.8	mg/dL	up to 30
Method : Tina-quant			

**Interpretation:**

**Note:** Lp(a) is considered an important risk factor for CHD especially among Indians as Indians tend to have high prevalence of elevated levels of Lp(a)

**Lp(a) in mg/dL**

(As per Lipid Association of India 2016)

**REMARKS**

<30	Low risk
30-49	Moderate Risk
>= 50	High risk

**Comments:**

Lipoprotein (a) [Lp(a)] consists of an LDL particle that is covalently bound to an additional protein, apolipoprotein (a) [Apo(a)]. Apo(a) has high-sequence homology with the coagulation factor plasminogen and, like LDL, Lp(a) contains apolipoprotein B100 (ApoB). Thus, Lp(a) is both proatherogenic and prothrombotic. Lp(a) is an independent risk factor for Coronary Heart Disease (CHD), Ischemic Stroke, and Aortic Valve Stenosis. Lp(a) is highly heterogeneous molecule; the degree of atherogenicity of the Lp(a) particle may depend on the molecular size of the Lp(a)-specific protein. Serum concentrations of Lp(a) are related to genetic factors, and are largely unaffected by diet, exercise and lipid-lowering pharmaceuticals. However, in a patient with additional modifiable CHD risk factors, more aggressive therapy to normalize these factors may be indicated if the Lp(a) value is also increased.

**Usage**

Evaluation of increased risk for cardiovascular disease and events:

- In individuals at intermediate risk for cardiovascular disease
- In patients with early atherosclerosis or
- In patients with strong family history of early CHD

Disclaimer: This is a sample report. The method and reference range in the actual report might vary as per lab accreditation or certification and equipments where sample is processed.

*Sohini Sengupta*

Dr. Sohini Sengupta  
MD (Cl Biochemistry), DNB,  
FNB (Lab Medicine)  
Medical Laboratory Director  
HOD (Biochemistry & Special Assays)



Booking Centre :- HOME COLLECTION - NOIDA - F10166

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

☎ 898-898-0606

✉ care@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.